Ironwood Pharma (IRWD) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Mizuho Reiterates Buy Rating and $21 PT on Ironwood Pharmaceuticals (IRWD) Following 4Q16 Results
February 22, 2017 5:52 AM ESTMizuho Securities analyst Irina Koffler reiterates Buy rating and $21 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), as the company reported 2016 fourth quarter revenues and EPS figures above consensus.
Koffler comments, "4Q:16 beat was great but not surprising since consensus largely omitted a $15M milestone associated with regulatory approval in Japan: IRWD reported 4Q:16 revenues of $87.5M... More
